| Type | Title | Date Released | |
|---|---|---|---|
6-K/A | Securities filing corrects convertible note and warrant floor price to $0.11952 from $0.11592; all other disclosures remain unchanged New | ||
6-K | SciSparc Enters $10 Million Securities Purchase Agreement and Issues Initial Convertible Note and Warrants | ||
6-K | Holder Agrees to Exercise Existing Warrants at Reduced Price, Expected to Generate Approximately $406,000 in Gross Proceeds | ||
6-K | Phase IIb Tourette Syndrome Trial Advances After Manufacturing Completion, European Batch Release and Clinical Site Readiness | ||
6-K | SciSparc Enters into Convertible Note Conversion Inducement Transaction with L.I.A Pure Capital | ||
6-K | SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies | ||
6-K | SciSparc’s Subsidiary NeuroThera Labs Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations | ||
6-K | SciSparc Ltd. Reports Interim Financial Results for the Period Ended June 30, 2026 | ||
6-K | SciSparc Subsidiary NeuroThera Expands U.S. Patent Portfolio in Collaboration with Clearmind | ||
6-K | SciSparc Subsidiary NeuroThera Labs Reports Enrollment Progress in SCI-210 Autism Clinical Trial | ||
EFFECT | Form EFFECT | ||
6-K | SciSparc Appoints AI Expert Prof. Carmel Domshlak to Scientific Advisory Board to Advance Agentic AI Strategy |
